Funded by the Autoimmune Encephalitis Alliance, Inc. (AE Alliance)
Call for Applications Announced: January 25, 2023
Application Deadline: April 28, 2023
Award Notification: June 2023
The AE Alliance is pleased to announce the call for applications to our third annual AEA Community Seed Grant Program to support research focused on the diagnosis, management, and outcomes of individuals with autoimmune encephalitis (AE).
This year, multiple grants of $10,000-$20,000 will be awarded. Based on donation stipulations, at least one grant will be awarded to a project focused on seronegative AE. While applications pertaining to clinical, basic, and/or translational research will be considered, proposed studies must have direct implications for patients with AE.
Submit all application documents (as PDFs) prior to the deadline by email to: email@example.com.
Applications will be reviewed by the AE Alliance Special Grants Review Committee, which includes members of the Research Sub-Committee of the AE Alliance’s Medical Advisory Board. Applications will be scored based on their scientific rigor, impact, and alignment with the AE Alliance Mission (as noted above). Committee members with a potential conflict of interest with the applicant or project will recuse themselves from the review of that application. Following the review of all applications, the committee will make a recommendation to the Board of Directors of the AE Alliance, which will have the final approval for funding.
EXPECTATIONS OF AEA COMMUNITY SEED GRANT RECIPIENTS
Communication with Seed Grant Funders (The AEA Community):
Project Duration: The project duration is no longer than 12 months (Project Start Date, 2023 – Project Start Date, 2024)
Reporting: Recipients must submit a final report to AE Alliance no later than 30 days following the end of the award period
Manuscripts: All manuscripts (including meeting abstracts and research papers in review) that result from this research project are to be submitted to the AE Alliance once they are accepted for publication. Publications should acknowledge support with the phrase: This project was financially supported by the Autoimmune Encephalitis Alliance.
Meg Poe, Director of Patient Support, Programs and Administration
Cognitive teleRehabilitation in patients with Encephalitis of AutoIMmune etiology: CoRE-AIM study
Dr. Matteo Gastaldi – C. Mondino National Institute of Neurology Foundation, IRCCS – Pavia, Italy
Predictors of Cognitive Outcomes in Children with Anti-NMDA Receptor Encephalitis
Dr. Leigh Sepeta & Dr. Elizabeth Wells – Children’s National Hospital – Washington DC, USA
Development of optimal clinical approaches in seronegative autoimmune encephalitis
Soon-Tae Lee, MD, PhD – Seoul National University Hospital – South-Korea
Patient Reported Outcomes while Manipulating the Immune System in autoimmune Encephalitis
Juna de Vries, MD, PhD – Erasmus University – The Netherlands
Subclinical activity in anti-LGI1 encephalitis: diagnostic tests and prognostic implications
Amaia Muñoz Lopetegi, MD – Hospital Clinic of Barcelona – Spain